172 related articles for article (PubMed ID: 37649296)
1. The role of aldose reductase in polyol pathway: An emerging pharmacological target in diabetic complications and associated morbidities.
Gupta JK
Curr Pharm Biotechnol; 2023 Aug; ():. PubMed ID: 37649296
[TBL] [Abstract][Full Text] [Related]
2. Physiological and Pathological Roles of Aldose Reductase.
Singh M; Kapoor A; Bhatnagar A
Metabolites; 2021 Sep; 11(10):. PubMed ID: 34677370
[TBL] [Abstract][Full Text] [Related]
3. Aldose Reductase: a cause and a potential target for the treatment of diabetic complications.
Thakur S; Gupta SK; Ali V; Singh P; Verma M
Arch Pharm Res; 2021 Jul; 44(7):655-667. PubMed ID: 34279787
[TBL] [Abstract][Full Text] [Related]
4. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
[TBL] [Abstract][Full Text] [Related]
5. In Search of Differential Inhibitors of Aldose Reductase.
Balestri F; Moschini R; Mura U; Cappiello M; Del Corso A
Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454074
[TBL] [Abstract][Full Text] [Related]
6. Aldose reductase, oxidative stress, and diabetic mellitus.
Tang WH; Martin KA; Hwa J
Front Pharmacol; 2012; 3():87. PubMed ID: 22582044
[TBL] [Abstract][Full Text] [Related]
7. Aldose reductase and its inhibition in the control of diabetic complications.
Narayanan S
Ann Clin Lab Sci; 1993; 23(2):148-58. PubMed ID: 8457142
[TBL] [Abstract][Full Text] [Related]
8. Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions.
Sonowal H; Ramana KV
Curr Med Chem; 2021; 28(19):3683-3712. PubMed ID: 33109031
[TBL] [Abstract][Full Text] [Related]
9. Aldose reductase / polyol inhibitors for diabetic retinopathy.
Obrosova IG; Kador PF
Curr Pharm Biotechnol; 2011 Mar; 12(3):373-85. PubMed ID: 20939801
[TBL] [Abstract][Full Text] [Related]
10. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
Suzen S; Buyukbingol E
Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
[TBL] [Abstract][Full Text] [Related]
11. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient.
Lorenzi M
Exp Diabetes Res; 2007; 2007():61038. PubMed ID: 18224243
[TBL] [Abstract][Full Text] [Related]
12. Potential use of aldose reductase inhibitors to prevent diabetic complications.
Zenon GJ; Abobo CV; Carter BL; Ball DW
Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
[TBL] [Abstract][Full Text] [Related]
13. Aldose reductase catalysis and crystallography. Insights from recent advances in enzyme structure and function.
Petrash JM; Tarle I; Wilson DK; Quiocho FA
Diabetes; 1994 Aug; 43(8):955-9. PubMed ID: 8039602
[TBL] [Abstract][Full Text] [Related]
14. Reduction of Glut1 in the Neural Retina But Not the RPE Alleviates Polyol Accumulation and Normalizes Early Characteristics of Diabetic Retinopathy.
Holoman NC; Aiello JJ; Trobenter TD; Tarchick MJ; Kozlowski MR; Makowski ER; De Vivo DC; Singh C; Sears JE; Samuels IS
J Neurosci; 2021 Apr; 41(14):3275-3299. PubMed ID: 33622781
[TBL] [Abstract][Full Text] [Related]
15. Vegetables' juice influences polyol pathway by multiple mechanisms in favour of reducing development of oxidative stress and resultant diabetic complications.
Tiwari AK; Kumar DA; Sweeya PS; Chauhan HA; Lavanya V; Sireesha K; Pavithra K; Zehra A
Pharmacogn Mag; 2014 Apr; 10(Suppl 2):S383-91. PubMed ID: 24991118
[TBL] [Abstract][Full Text] [Related]
16. Aldose reductase in diabetic microvascular complications.
Chung SS; Chung SK
Curr Drug Targets; 2005 Jun; 6(4):475-86. PubMed ID: 16026266
[TBL] [Abstract][Full Text] [Related]
17. Aldose reductase and the role of the polyol pathway in diabetic nephropathy.
Dunlop M
Kidney Int Suppl; 2000 Sep; 77():S3-12. PubMed ID: 10997684
[TBL] [Abstract][Full Text] [Related]
18. Natural Compounds as Source of Aldose Reductase (AR) Inhibitors for the Treatment of Diabetic Complications: A Mini Review.
Grewal AS; Thapa K; Kanojia N; Sharma N; Singh S
Curr Drug Metab; 2020; 21(14):1091-1116. PubMed ID: 33069193
[TBL] [Abstract][Full Text] [Related]
19. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
20. Development, Molecular Docking, and
Imran A; Shehzad MT; Shah SJA; Laws M; Al-Adhami T; Rahman KM; Khan IA; Shafiq Z; Iqbal J
ACS Omega; 2022 Aug; 7(30):26425-26436. PubMed ID: 35936488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
